The Implications of Intellectual Property Protection for Biologics

There are real problems of, I think, excessive incentive laring in the IP protections for biologics. A lot of these patents are patents on the manufacturing process. The FDA is tougher on you when you try to get a biosemolar through. And as an originator manufacturer, you have 12 years of data exclusivity over your original clinical trial data.